Ionis Pharma announced a Phase 2b study conducted by Pfizer and evaluating vupanorsen (formerly IONIS-ANGPTL3-LRx) for patients with elevated non-HDL-C and triglycerides has met its…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.